Jeng-Sen Tseng (Jia-Jun Wu)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Hepatitis B Virus

Top Venues

International journal of molecular sciences

Journal of clinical medicine

Therapeutic advances in medical oncology

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor. International journal of molecular sciences 25 (1) (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Po-Hsin Lee, Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. International journal of molecular sciences 25 (13) (2024)
Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor. International journal of molecular sciences 25 (1) (2024)
Po-Hsin Lee, Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. International journal of molecular sciences 25 (13) (2024)
Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor. International journal of molecular sciences 25 (1) (2024)
Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor. International journal of molecular sciences 25 (1) (2024)
Wei-Fan Ou, Pei-Ya Liao, Yu-Wei Hsu, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. Cancer management and research 15 (2023)
Kuan-Chih Chen, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR -Mutant NSCLC Patients Treated with First-Line Osimertinib. OncoTargets and therapy 16 (2023)
Po-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, Kun-Chieh Chen, Kuo-Hsuan Hsu, Chung-Jung Lin, Teng-Yu Lee, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. Journal of clinical medicine 12 (1) (2022)
Po-Hsin Lee, Yen-Hsiang Huang, Chung-Jung Lin, Kuo-Hsuan Hsu, Kun-Chieh Chen, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR -Mutant Lung Adenocarcinoma. Medicina (Kaunas, Lithuania) 58 (7) (2022)
Cheng-Hsiang Chu, Yen-Hsiang Huang, Po-Hsin Lee, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
Various impacts of driver mutations on the PD-L1 expression of NSCLC. PloS one 17 (8) (2022)
Po-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, Kun-Chieh Chen, Kuo-Hsuan Hsu, Chung-Jung Lin, Teng-Yu Lee, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. Journal of clinical medicine 12 (1) (2022)
Po-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, Kun-Chieh Chen, Kuo-Hsuan Hsu, Chung-Jung Lin, Teng-Yu Lee, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. Journal of clinical medicine 12 (1) (2022)
Po-Hsin Lee, Yen-Hsiang Huang, Yu-Wei Hsu, Kun-Chieh Chen, Kuo-Hsuan Hsu, Chung-Jung Lin, Teng-Yu Lee, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. Journal of clinical medicine 12 (1) (2022)
Chun Lin, Tsung-Ying Yang, Ming-Cheng Chan, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng
Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients. Journal of fungi (Basel, Switzerland) 7 (8) (2021)